Olaratumab, previously identified as LY3012207 and subsequently recognized as IMC-3G3, represents a unique novel monoclonal antibody therapeutic agent targeting the tumor-associated glycoprotein podoplanin PDPN gp38. https://shaunakbgl615238.blog5.net/92404327/olaratumab-a-deep-investigation-analysis-into-ly3012207-and-imc-3g3